Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Dec 07, 2023 8:36am
264 Views
Post# 35772633

RE:Baxter

RE:Baxter

Hey Glenview 

An excellent deduction worth exploring.

Some might say, " but all material contracts have to be disclosed"

Do they ?

Perhaps not if they are in some ways "contingent" on a future event that has yet to happen ( eg FDA approval) or

perhaps not if the value of the contract, understanding or MOU could not be reasonably quantified , say for example if the price was variable based on certain other events ( eg final risk reduction percentages, completion of ancillary studies supporting expanded use,  etc.) 

Still others might say how can a deal be made when they're not at 150, or why would they stop at 90, if they're going to all the trouble of adding new sites?. Well what's to stop another new entity from taking over the Trial and seeing it to its logical & formal conclusion? Particularly one skilled in all matters of ongoing relationships with both hospitals and the FDA? 

Still others might argue, "why would some Company pay the big bucks when their is uncertainty of outcome?"  Those people might be well advised to read Kellum's latest Bayesian analysis paper, and then factor in results that are " exceeding expectations"  - especially if they are entitled to a hard look at the data. 


Anyway. 


Good & worthy speculation Glenview. 


MM 

 

<< Previous
Bullboard Posts
Next >>